US Pharma MarketingFDA places partial hold on Biohaven
An epilepsy study of the experimental drug called BHV-7000 was paused after regulators requested more information about preclinical safety data, Biohaven revealed in an SEC filing. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and…
The FDA has placed a troubled Biohaven program on partial clinical hold, the company disclosed Wednesday.
An epilepsy study of the experimental drug called BHV-7000 was paused after regulators requested more information about preclinical safety ...
Source: Endpoints News